Moody Lynn & Lieberson LLC Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Moody Lynn & Lieberson LLC increased its stake in Vertex Pharmaceuticals by 1.4%, acquiring a total of 58,077 shares, valued at approximately $25.86 million at the end of the reporting period.
• Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals at an average price of $389.68 per share, increasing his holdings by 12.5% to a total of 45,000 shares.
• Vertex Pharmaceuticals has seen mixed analyst ratings, with two analysts rating it as a Strong Buy, while the overall average rating remains a "Moderate Buy" with a target price of $493.81.

Moody Lynn & Lieberson LLC grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,077 shares of the pharmaceutical company's stock after buying an additional 822 shares during the period. Vertex Pharmaceuticals accounts for approximately 1.5% of Moody Lynn & Lieberson LLC's holdings, making the stock its 22nd biggest holding. Moody Lynn & Lieberson LLC's holdings in Vertex Pharmaceuticals were worth $25,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. United Services Automobile Association purchased a new position in Vertex Pharmaceuticals in the first quarter valued at approximately $2,933,000. Aries Wealth Management purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $293,000. New England Research & Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $472,000. Paladin Wealth LLC purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $552,000. Finally, Andrew Hill Investment Advisors Inc. increased its holdings in Vertex Pharmaceuticals by 21.8% in the 2nd quarter. Andrew Hill Investment Advisors Inc. now owns 8,003 shares of the pharmaceutical company's stock valued at $3,563,000 after purchasing an additional 1,430 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Canaccord Genuity Group reduced their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating on the stock in a research note on Wednesday, August 6th. Guggenheim dropped their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research note on Tuesday, August 5th. Leerink Partners raised shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and dropped their price target for the stock from $458.00 to $456.00 in a research note on Thursday. Finally, Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They issued a "market perform" rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $493.81.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $385.73 on Monday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The company has a market capitalization of $98.90 billion, a price-to-earnings ratio of 27.57 and a beta of 0.44. The company's fifty day moving average price is $406.00 and its two-hundred day moving average price is $445.87.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the firm earned ($12.83) EPS. The company's revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.